Jyoti Resins and Adhesives manufactures and sells synthetic wood adhesives, primarily white glue, under the Euro 7000 brand to carpenters and retail dealers across India.
The company possesses a narrow moat driven by brand recognition among carpenters and a robust loyalty program that creates switching costs. While high ROCE supports this, the lack of pricing power during raw material spikes (VAM) suggests the moat is not yet wide enough to fully insulate margins.
Management has maintained a debt-free balance sheet while funding capacity expansions (from 2,000 to 3,500 TPM) entirely through internal accruals. They prioritize reinvestment in brand building and distribution over dividends, though they maintain a consistent 15% payout ratio.
The investment collapsed as the company's aggressive expansion to 3,500 TPM coincided with a prolonged spike in VAM prices that they could not pass on to consumers. The massive carpenter bonus liability, which was already nearly 100 Cr, ballooned further and became a liquidity trap as cash conversion remained abysmal. As receivable days stretched beyond 160, the working capital cycle broke, forcing the debt-free firm to take on high-interest loans just to fund operations, ultimately eroding the high ROCE that once justified its premium.
RichFakir rates Jyoti Resins and Adhesives Ltd's business quality as wonderful — 72/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Jyoti Resins and Adhesives Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Jyoti Resins and Adhesives Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Jyoti Resins and Adhesives Ltd's fair value is about ₹307 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →